Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome
Background: Non-Hodgkin’s lymphoma (NHL) in patients older than 80 years is not a rare disease and treatment strategies are often difficult because of associated comorbidities. Patients and methods: We entered 205 NHL patients older than 80 years treated in a single institution in a retrospective an...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2008-04, Vol.19 (4), p.774-779 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 779 |
|---|---|
| container_issue | 4 |
| container_start_page | 774 |
| container_title | Annals of oncology |
| container_volume | 19 |
| creator | Thieblemont, C. Grossoeuvre, A. Houot, R. Broussais-Guillaumont, F. Salles, G. Traullé, C. Espinouse, D. Coiffier, B. |
| description | Background: Non-Hodgkin’s lymphoma (NHL) in patients older than 80 years is not a rare disease and treatment strategies are often difficult because of associated comorbidities. Patients and methods: We entered 205 NHL patients older than 80 years treated in a single institution in a retrospective analysis to describe clinical presentation and outcome and to identify specific prognostic factors. Results: The median age was 83 years, and 91% of the cases were B-cell lymphomas consisting mainly of diffuse large B-cell lymphoma and marginal zone lymphoma. Among patients presenting comorbidities (87%), Charlson index was low in almost half of the patients (43%). Patients did not receive any treatment or received corticosteroids alone in 15%, surgery, radiotherapy, or monochemotherapy in 35%, polychemotherapy without anthracycline in 18%, and anthracycline based in 32%. Median overall survival was of 2.2 years. Main reason for death was disease progression (57%). Independent prognostic factors of survival were poor performance status (P |
| doi_str_mv | 10.1093/annonc/mdm563 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70433091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdm563</oup_id><sourcerecordid>1452539951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c555t-146219ed8f0e0749ddfbe31d613cb939abf999c405d2085142fe60b2d96a31dc3</originalsourceid><addsrcrecordid>eNqF0U9r1jAcB_AiinucHr1KEBQv3fK_zXEO3aOO6UFheAlpkmq2NumSdljw4NvY29srMQ8tE7zsFAiffJNfvkXxHMEDBAU5VN4Hrw970zNOHhQbxLgoa0jRw2IDBSZlxQjdK56kdAEh5AKLx8UeqiFnFNJN8fss-HIbzI9L52__3CTQzf3wM_QKOA-ubZyB7YyN3QwGNTrrxwRC3gY1BLNVMR2AI2Bs0tENo7u2QHnVzcll1QLdOe-06sAQbcpHc0DwWRgQplGH3j4tHrWqS_bZuu4X396_-3q8LU8_n3w4PjotNWNsLBHlGAlr6hZaWFFhTNtYggxHRDeCCNW0QghNITMY1gxR3FoOG2wEV5lpsl-8XnKHGK4mm0bZu6Rt1ylvw5RkBSkhUKB7IRK0IljQDF_-By_CFPPsO8M5E7iqMyoXpGNIKdpWDtH1Ks4SQbkrTy7lyaW87F-soVPTW_NPr21l8GoFKuV_baPy2qU7hyHGFal2Y7xZXJiGe-9c3-jSaH_dYRUvJc9ZTG7Pv8uTj5_w-dsvQp6Rvyj3wvA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196659278</pqid></control><display><type>article</type><title>Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Thieblemont, C. ; Grossoeuvre, A. ; Houot, R. ; Broussais-Guillaumont, F. ; Salles, G. ; Traullé, C. ; Espinouse, D. ; Coiffier, B.</creator><creatorcontrib>Thieblemont, C. ; Grossoeuvre, A. ; Houot, R. ; Broussais-Guillaumont, F. ; Salles, G. ; Traullé, C. ; Espinouse, D. ; Coiffier, B.</creatorcontrib><description>Background: Non-Hodgkin’s lymphoma (NHL) in patients older than 80 years is not a rare disease and treatment strategies are often difficult because of associated comorbidities. Patients and methods: We entered 205 NHL patients older than 80 years treated in a single institution in a retrospective analysis to describe clinical presentation and outcome and to identify specific prognostic factors. Results: The median age was 83 years, and 91% of the cases were B-cell lymphomas consisting mainly of diffuse large B-cell lymphoma and marginal zone lymphoma. Among patients presenting comorbidities (87%), Charlson index was low in almost half of the patients (43%). Patients did not receive any treatment or received corticosteroids alone in 15%, surgery, radiotherapy, or monochemotherapy in 35%, polychemotherapy without anthracycline in 18%, and anthracycline based in 32%. Median overall survival was of 2.2 years. Main reason for death was disease progression (57%). Independent prognostic factors of survival were poor performance status (P < 10−4) and high lactate dehydrogenase level (P < 10−5). Comorbidities were not found to influence survival. Conclusions: Very elderly NHL patients showed similar features and prognostic factors than younger patients. Death was related mainly to the disease, meaning that these patients should be more frequently treated with standard treatments.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdm563</identifier><identifier>PMID: 18065404</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Aged, 80 and over ; Anthracyclines - administration & dosage ; Antibiotics, Antineoplastic - administration & dosage ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Chemotherapy, Adjuvant ; Comorbidity ; comorbities ; Diagnosis, Differential ; Disease Progression ; Female ; Hematologic and hematopoietic diseases ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; lymphoma ; Lymphoma, Large B-Cell, Diffuse - diagnosis ; Lymphoma, Large B-Cell, Diffuse - therapy ; Lymphoma, Non-Hodgkin - diagnosis ; Lymphoma, Non-Hodgkin - drug therapy ; Lymphoma, Non-Hodgkin - mortality ; Lymphoma, Non-Hodgkin - radiotherapy ; Lymphoma, Non-Hodgkin - surgery ; Lymphoma, Non-Hodgkin - therapy ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Prognosis ; prognostic factors ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Analysis ; Treatment Outcome ; very elderly patients</subject><ispartof>Annals of oncology, 2008-04, Vol.19 (4), p.774-779</ispartof><rights>The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008</rights><rights>2008 INIST-CNRS</rights><rights>The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c555t-146219ed8f0e0749ddfbe31d613cb939abf999c405d2085142fe60b2d96a31dc3</citedby><cites>FETCH-LOGICAL-c555t-146219ed8f0e0749ddfbe31d613cb939abf999c405d2085142fe60b2d96a31dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20227371$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18065404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thieblemont, C.</creatorcontrib><creatorcontrib>Grossoeuvre, A.</creatorcontrib><creatorcontrib>Houot, R.</creatorcontrib><creatorcontrib>Broussais-Guillaumont, F.</creatorcontrib><creatorcontrib>Salles, G.</creatorcontrib><creatorcontrib>Traullé, C.</creatorcontrib><creatorcontrib>Espinouse, D.</creatorcontrib><creatorcontrib>Coiffier, B.</creatorcontrib><title>Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: Non-Hodgkin’s lymphoma (NHL) in patients older than 80 years is not a rare disease and treatment strategies are often difficult because of associated comorbidities. Patients and methods: We entered 205 NHL patients older than 80 years treated in a single institution in a retrospective analysis to describe clinical presentation and outcome and to identify specific prognostic factors. Results: The median age was 83 years, and 91% of the cases were B-cell lymphomas consisting mainly of diffuse large B-cell lymphoma and marginal zone lymphoma. Among patients presenting comorbidities (87%), Charlson index was low in almost half of the patients (43%). Patients did not receive any treatment or received corticosteroids alone in 15%, surgery, radiotherapy, or monochemotherapy in 35%, polychemotherapy without anthracycline in 18%, and anthracycline based in 32%. Median overall survival was of 2.2 years. Main reason for death was disease progression (57%). Independent prognostic factors of survival were poor performance status (P < 10−4) and high lactate dehydrogenase level (P < 10−5). Comorbidities were not found to influence survival. Conclusions: Very elderly NHL patients showed similar features and prognostic factors than younger patients. Death was related mainly to the disease, meaning that these patients should be more frequently treated with standard treatments.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Aged, 80 and over</subject><subject>Anthracyclines - administration & dosage</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy, Adjuvant</subject><subject>Comorbidity</subject><subject>comorbities</subject><subject>Diagnosis, Differential</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - diagnosis</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Lymphoma, Non-Hodgkin - diagnosis</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Lymphoma, Non-Hodgkin - mortality</subject><subject>Lymphoma, Non-Hodgkin - radiotherapy</subject><subject>Lymphoma, Non-Hodgkin - surgery</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>very elderly patients</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U9r1jAcB_AiinucHr1KEBQv3fK_zXEO3aOO6UFheAlpkmq2NumSdljw4NvY29srMQ8tE7zsFAiffJNfvkXxHMEDBAU5VN4Hrw970zNOHhQbxLgoa0jRw2IDBSZlxQjdK56kdAEh5AKLx8UeqiFnFNJN8fss-HIbzI9L52__3CTQzf3wM_QKOA-ubZyB7YyN3QwGNTrrxwRC3gY1BLNVMR2AI2Bs0tENo7u2QHnVzcll1QLdOe-06sAQbcpHc0DwWRgQplGH3j4tHrWqS_bZuu4X396_-3q8LU8_n3w4PjotNWNsLBHlGAlr6hZaWFFhTNtYggxHRDeCCNW0QghNITMY1gxR3FoOG2wEV5lpsl-8XnKHGK4mm0bZu6Rt1ylvw5RkBSkhUKB7IRK0IljQDF_-By_CFPPsO8M5E7iqMyoXpGNIKdpWDtH1Ks4SQbkrTy7lyaW87F-soVPTW_NPr21l8GoFKuV_baPy2qU7hyHGFal2Y7xZXJiGe-9c3-jSaH_dYRUvJc9ZTG7Pv8uTj5_w-dsvQp6Rvyj3wvA</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Thieblemont, C.</creator><creator>Grossoeuvre, A.</creator><creator>Houot, R.</creator><creator>Broussais-Guillaumont, F.</creator><creator>Salles, G.</creator><creator>Traullé, C.</creator><creator>Espinouse, D.</creator><creator>Coiffier, B.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20080401</creationdate><title>Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome</title><author>Thieblemont, C. ; Grossoeuvre, A. ; Houot, R. ; Broussais-Guillaumont, F. ; Salles, G. ; Traullé, C. ; Espinouse, D. ; Coiffier, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c555t-146219ed8f0e0749ddfbe31d613cb939abf999c405d2085142fe60b2d96a31dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Aged, 80 and over</topic><topic>Anthracyclines - administration & dosage</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy, Adjuvant</topic><topic>Comorbidity</topic><topic>comorbities</topic><topic>Diagnosis, Differential</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - diagnosis</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Lymphoma, Non-Hodgkin - diagnosis</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Lymphoma, Non-Hodgkin - mortality</topic><topic>Lymphoma, Non-Hodgkin - radiotherapy</topic><topic>Lymphoma, Non-Hodgkin - surgery</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>very elderly patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thieblemont, C.</creatorcontrib><creatorcontrib>Grossoeuvre, A.</creatorcontrib><creatorcontrib>Houot, R.</creatorcontrib><creatorcontrib>Broussais-Guillaumont, F.</creatorcontrib><creatorcontrib>Salles, G.</creatorcontrib><creatorcontrib>Traullé, C.</creatorcontrib><creatorcontrib>Espinouse, D.</creatorcontrib><creatorcontrib>Coiffier, B.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thieblemont, C.</au><au>Grossoeuvre, A.</au><au>Houot, R.</au><au>Broussais-Guillaumont, F.</au><au>Salles, G.</au><au>Traullé, C.</au><au>Espinouse, D.</au><au>Coiffier, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>19</volume><issue>4</issue><spage>774</spage><epage>779</epage><pages>774-779</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: Non-Hodgkin’s lymphoma (NHL) in patients older than 80 years is not a rare disease and treatment strategies are often difficult because of associated comorbidities. Patients and methods: We entered 205 NHL patients older than 80 years treated in a single institution in a retrospective analysis to describe clinical presentation and outcome and to identify specific prognostic factors. Results: The median age was 83 years, and 91% of the cases were B-cell lymphomas consisting mainly of diffuse large B-cell lymphoma and marginal zone lymphoma. Among patients presenting comorbidities (87%), Charlson index was low in almost half of the patients (43%). Patients did not receive any treatment or received corticosteroids alone in 15%, surgery, radiotherapy, or monochemotherapy in 35%, polychemotherapy without anthracycline in 18%, and anthracycline based in 32%. Median overall survival was of 2.2 years. Main reason for death was disease progression (57%). Independent prognostic factors of survival were poor performance status (P < 10−4) and high lactate dehydrogenase level (P < 10−5). Comorbidities were not found to influence survival. Conclusions: Very elderly NHL patients showed similar features and prognostic factors than younger patients. Death was related mainly to the disease, meaning that these patients should be more frequently treated with standard treatments.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>18065404</pmid><doi>10.1093/annonc/mdm563</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2008-04, Vol.19 (4), p.774-779 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70433091 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adrenal Cortex Hormones - therapeutic use Aged, 80 and over Anthracyclines - administration & dosage Antibiotics, Antineoplastic - administration & dosage Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy, Adjuvant Comorbidity comorbities Diagnosis, Differential Disease Progression Female Hematologic and hematopoietic diseases Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis lymphoma Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - therapy Lymphoma, Non-Hodgkin - diagnosis Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - radiotherapy Lymphoma, Non-Hodgkin - surgery Lymphoma, Non-Hodgkin - therapy Male Medical sciences Pharmacology. Drug treatments Prognosis prognostic factors Radiotherapy, Adjuvant Retrospective Studies Survival Analysis Treatment Outcome very elderly patients |
| title | Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T19%3A06%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-Hodgkin%E2%80%99s%20lymphoma%20in%20very%20elderly%20patients%20over%2080%20years.%20A%20descriptive%20analysis%20of%20clinical%20presentation%20and%20outcome&rft.jtitle=Annals%20of%20oncology&rft.au=Thieblemont,%20C.&rft.date=2008-04-01&rft.volume=19&rft.issue=4&rft.spage=774&rft.epage=779&rft.pages=774-779&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdm563&rft_dat=%3Cproquest_cross%3E1452539951%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196659278&rft_id=info:pmid/18065404&rft_oup_id=10.1093/annonc/mdm563&rfr_iscdi=true |